Matthew Breeggemann, MD
Nephrology · San Francisco, CANPI 1083077549
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,975 of the $18,779 with a category attached, or 69.1%. 4 manufacturers reported payments, led by Novo Nordisk AS at 47.4% of the total. Reporting peaked in 2024 at $9,364 and has fallen 50.7% since, to $4,619 in 2025. Among nephrology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 39 payments — averaging $481.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$9K
- Novo Nordisk Health Care AG$4K
- Novo Nordisk$4K
- Alnylam Pharmaceuticals Inc.$1K
What the payments were for
- Consulting fees$12,97569%
- Speaking & faculty fees$1,4158%
- Travel & lodging$2,43913%
- Food & beverage$1,88610%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 6 | $8,904 |
| Novo Nordisk Health Care AG | 7 | $4,435 |
| Novo Nordisk | 19 | $4,292 |
| Alnylam Pharmaceuticals Inc. | 7 | $1,148 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,779 in reported general payments places this provider in the 90th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 15 | $21,845 |
| Potassium Citrate ErPotassium Citrate | 20 | $4,319 |
| Chlorthalidone | 28 | $470 |
| Potassium Chloride | 11 | $356 |
| Tamsulosin Hcl | 14 | $314 |
| Lisinopril | 18 | $172 |
| Losartan Potassium | 28 | $151 |
| Furosemide | 14 | $67 |
Paid to pharmacies, not to this prescriber.
Other nephrology in San Francisco
- Meyeon ParkSan Francisco$119K
- Raymond HsuSan Francisco$77K
- Fred LuiSan Francisco$68K
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.